DAVID GRANOVSKY

Posts Tagged ‘msc’

ADULT STEM CELL EVOLUTION AT A GLANCE

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on July 16, 2014 at 11:03 am

“Beginning in about 1990, the treatment of cardiovascular disease experienced major conceptual expansions through the application of new therapeutic paradigms targeted to angiogenesis and tissue healing. Initial strategies involved administering proteins involved in healing processes, then the genes that encoded them, and then, by the end of the decade, the use of stem cells to better achieve these objectives.” -‘Stem Cell Therapy in Cardiovascular Disease: Past Obstacles and Promising New Directions‘, genengnews.com

Stem Cell Therapy in Cardiovascular Disease: Past Obstacles and Promising New Directions

Adult Stem Cell Evolution At A Glance
Author: Sarah Hoffman

I know many people think that what we know about stem cells is all we have ever known. This is a misconception arising from the fact that people in the United States do not discuss the topic because it could be considered a political no-no-topic. In reality, many scientists from all over the earth research adult stem cells and are finding ways to use them that was never before imaginable. They are also perfecting ways in which we use them to treat patience with varying ailments. This article focuses on cardiovascular diseases.

Scientists began by trying varying methods of stem cell treatment, from utilizing many different types of cells at a time to using very specific cells. Through many studies and trial and error, scientists found that intravenous injection of stem cells to treat many cardiac ailments was effective, efficient, and affordable.

So it seems to me that a routine stem cell treatment may soon be available to cardiac patients.

Take a gander at the whole article and I know some more of your questions are sure to be answered!

FOR REGENERATIVE MEDICINE, ADIPOSE (FAT) STEM CELLS ARE BEST

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 26, 2013 at 10:41 am

david

50% MORE REGENERATIVE STEM CELLS IN FAT THAN IN CORD BLOOD: 

“Adult stem cells are derived from blood, umbilical cords, bone marrow, placenta, fat tissue, muscle, nasal neurological, breast milk, menstruation, dental pulp, lungs, eyes, pancreas and many more locations. While some are better than others for regenerative treatment, it has long been believed that those cells derived from reproductive associated organs are some of the most powerful.  This study shows that umbilical cord derived stem cells are not as great as once believed.”

In fact, compared to the 100% of mesenchymal stem cells found in cells derived from adipose (fat), only 67% of cord blood stem cells are mesenchymal and lend themselves toward regenerative treatments.*  While bone marrow derived stem cells also have 100% mesenchymal cells, they have reduced proliferation and have a history of causing malignant cells – ‘In addition, Izadpanah et al.** demonstrated that long-term cultivation of MSC beyond passage 20 may result in their transformation to malignant cells.”***


For regenerative medicine, nothing beats adipose derived stem cells. -dg

umbilical-cord-blood

Only A Specific Group Of Cord Blood Stem Cells Found To Be Efficient For Use In Regenerative Medicine

Scientists at the University of Granada and Alcala de Henares University have found that not all isolated stem cells are equally valid in regenerative medicine and tissue engineering. In a paper recently published in the prestigious journal Tissue Engineering the researchers report that, contrary to what was thought, only a specific group of cord blood stem cells (CB-SC) maintained in culture are useful for therapeutic purposes.

At present, CB-SCs are key to regenerative medicine and tissue engineering. From all types of CB-SC those called “Wharton’s jelly stem cells (HWJSC)” are stirring up the interest of specialists in regenerative medicine, due to their accessibility and great ability to develop into several types of tissue and modulate immune responses.

Through a combination of microscopy and microanalysis essays, and the study of the genes involved in cell viability, the researchers discovered that only a specific group of cord blood stem cells (CB-SC) maintained in culture is useful for therapeutic purposes

The Most Suitable Cells

The relevance of this paper, which was the cover article in the journal Tissue Engineering, lies in the possibility to select the most suitable HWJSC for tissue engineering and regenerative medicine. According to these researchers, the different studies with HWJSC have obtained contradictory results because researchers failed to previously select the most suitable cell group.

The results of this study also open the possibility to select stem cell subgroups from different tissues, in order to improve the therapeutical efficacy of different regenerative medicine protocols.

This research study was conducted by the Tissue Engineering research group at the University of Granada Histology Department coordinated by professor Antonio Campos Muñoz, who recently created artificial skin and a cornea by using stem cells and new biomaterials developed in Granada.

The research group is also composed of professors Alaminos Mingorance and Ingrid Garzón. Professor Garzon was awarded a prize at the World Congress on Tissue Engineering and Regenerative Medicine held in Seul for a preliminary study on the same issue.

http://www.medicalnewstoday.com/releases/254790.php

* , *** Stem Cells. 2006 May;24(5):1294-301. Epub 2006 Jan 12.

** – Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res.                                                           2008;68:4229–4238.

STEM CELLS FOR MS – HOW THEY WORK DISCOVERED

In VICTORIES & SUCCESS STORIES on September 5, 2012 at 2:32 pm

 

Cleveland researchers find key to stem-cell therapy for MS patients: Discoveries
Published: Tuesday, September 04, 2012, 7:21 AM     Updated: Tuesday, September 04, 2012, 2:02 PM

CLEVELAND, Ohio — …Figuring out why the mice improved could help researchers see if the MSC injection will work well in a particular patientbefore the patient is injected, and possibly augment or improve the treatment as well.

In May, the research group atCWRU, headed up by neurosciences professor Robert Miller, discovered exactly what it is in the stem-cell soup that has a healing effect: a large molecule called hepatocyte growth factor, or HGF. The team published their results in Nature Neuroscience.

Miller’s group knew that it could be the stem cells themselves, by coming in physical contact with the myelin damage, that were having a healing effect. Or it could be something the stem cells secreted into the surrounding liquid culture, or media, they were grown in, that was key. HGF is secreted by the stem cells, Miller said.

The team identified the HGF by first injecting only the liquid the stem cells were grown in, but not the stem cells themselves, into the mice they were studying. The mice got better, so the team knew whatever was helping was in the media.

Next, they isolated the small, medium and large molecules from the media and tried each size on the mice. Only the large-molecule treatment had the healing effect, meaning that whatever was helping was somewhere in that mix, Miller said.

“The molecule that jumped out at us was HGF,” he said, because it is the right size, is made by MSCs, and in a couple ofstudies had been shown to be involved in myelin repair.

So the scientists took a purified sample of HGF and injected it into the sick mice. They got better. When they blocked the receptor for HGF in the mice, they stayed sick. It was pretty compelling evidence that they’d found what they’d been looking for, Miller said.

“We went on to show that HGF, like the MSCs, is regulating both the immune response, and it is independently promoting myelin repair in the brain,” he said.

MSCs, taken from the bone marrow, are currently being tested in more than 150 clinical trials in the United States and around the world to treat conditions such as osteoarthritis, diabetes, emphysema and stroke.

JEFFREY-COHEN-CLEVELAND-CLINIC.JPG

The local Phase 1 trial has enrolled 16 of 24 total patients, and eight of them have completed the trial protocol, said Dr. Jeffrey Cohen, Cleveland Clinic neurologist and lead investigator of the trial.

So far, the treatment seems to be working, Cohen said.

“It’s a little early to be saying it, but things have looked encouraging.”

And there have been no safety concerns and almost no side effects. There has also been no activation — an aggravation or return of symptoms — of this relapsing disease in the patients involved, which has happened unexpectedly with other types of MS treatments.

Miller’s discovery won’t change the course of the trial currently under way at the Clinic and UH, but it may change the future of MSC treatment.

While they don’t know yet what the outcome of that trial will be, it’s possible that if a patient doesn’t respond to the treatment, it could mean that hisstem cells aren’t producing enough HGF to be effective at healing, Miller said. Miller will be studying MSC samples from all the patients in the trial to find out if those who are better at producing HGF fare better.

He’ll also be trying to see if they can predict how well a patient will do based on hisHGF levels in the MSC sample…

“Finally, though we’re a long way from this, maybe we could augment the expression of HGF in patients whose stem cells aren’t that effective to enhance their effectiveness,” he said.

But why not just inject the HGF alone? Miller said there are two reasons. First, the receptor for HGF in the cells, called c-MET, has been implicated in liver and breast cancer. Injecting HGF by itself into the body may stimulate the c-MET pathway, he said, and the research team is not willing to risk that.

“The stem cells have the advantage that they tend to home to the area of insult, so they don’t stick around in other parts of the body,” he said. “They target the treatment where it’s needed.”

http://www.cleveland.com/healthfit/index.ss

MSC2009 – Adult Stem Cell Conference – Vitacyte

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:22 pm

CLEVELAND, Ohio –MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.

Vodpod videos no longer available.

VitaCyte is a startup cell-isolation company that has started using stem cells in its product lines, which include manufacturing reagents, kits and purified cells to be used in the academic or commercial setting. The company uses enzymes to isolate certain cells in the hopes of speeding the production and discovery process in a lab.

via  http://www.medcitynews.com/index.php/2009/08/video-3-stem-cell-businesses-at-msc2009/

%d bloggers like this: